In this article, we will list the 5 Quality Value Stocks Likely to Make a Comeback According to Analysts. Please visit 10 Quality Value Stocks Likely to Make a Comeback According to Analysts if you’d like to see an extended list and how we came up with the top stocks that could make a comeback.
5. Futu Holdings Limited (NASDAQ:FUTU)
Price Target Upside: 62.68%
Futu Holdings Limited (NASDAQ:FUTU) is among the best value stocks to invest in.
TheFly reported on March 16 that Barclays kept an Overweight rating on FUTU while reducing its price target from $236 to $200. The company added roughly 230,000 new paying clients in the fourth quarter, and management projects around 800,000 additional paying clients for 2026. The rating reflects Barclays’ view of the company’s continued growth in its client base and market presence.
On March 12, 2026, Futu Holdings Limited (NASDAQ:FUTU) reported its fourth quarter and full year 2025 results, showing strong revenue and earnings growth. Fourth quarter revenue reached HK$6,438.5 million (US$827.2 million), up 45.3% year-over-year, driven by higher trading volume and increased interest income from securities lending, margin financing, and bank deposits. Gross profit rose 56.2% to HK$5,709.7 million (US$733.6 million), with an 88.7% margin. Net income climbed 80.2% to HK$3,369.4 million (US$432.9 million), while non-GAAP net income grew 77.0% to HK$3,455.7 million (US$444.0 million).
For the full year, revenues increased 68.1% to HK$22,846.9 million (US$2,935.4 million) and net income more than doubled to HK$11,301.9 million (US$1,452.1 million). EPS per ADS rose substantially, reflecting strong operational performance and leverage across the business.
Futu Holdings Limited (NASDAQ:FUTU) is a Hong Kong‑based fintech company offering fully digital brokerage, wealth management, and investing services via its Futubull and moomoo platforms, including trading, market data, financing, and global asset access to individual and institutional investors.
4. Alaska Air Group, Inc. (NYSE:ALK)
Price Target upside: 68.16%
Alaska Air Group, Inc. (NYSE:ALK) is one of the best value stocks on this list.
TheFly reported on March 23 that BMO Capital began coverage of ALK with an Outperform rating and a $50 price objective. The firm pointed to long-term earnings expansion potential despite limited near-term clarity around fuel costs. BMO also highlighted upside tied to ALK’s strategic plans, including the integration of Hawaiian Airlines, debt reduction efforts, and its shift toward becoming an international carrier.
Separately, on March 13, the University of Washington and Alaska Air Group, Inc. (NYSE:ALK) confirmed a new 10-year agreement extending Alaska Airlines’ naming rights for the Alaska Airlines Arena at Hec Edmundson Pavilion. The renewed deal also broadens the partnership’s focus on student-athlete support and community involvement. Alaska Airlines will remain the university’s Official Airline while continuing its branding across UW athletics, including football at Husky Stadium. A significant portion of ALK’s annual financial commitment will go toward scholarships and community-based programs that benefit UW student-athletes, as well as major events involving alumni, fans, and supporters.
The agreement also keeps ALK involved in several campus and fan-centered initiatives, including sponsored events, student reward programs, alumni experiences, and continued support for university-related business and innovation programs. The partnership reinforces the close connection between the airline and the university, both of which are deeply tied to Seattle and share broader goals centered on education, outreach, and long-term community impact.
Alaska Air Group, Inc. (NYSE:ALK) is a U.S. airline holding company that operates Alaska Airlines, Hawaiian Airlines, and Horizon Air, providing passenger and cargo services across North America, Latin America, Asia, and the Pacific.
3. Orla Mining Ltd. (NYSE:ORLA)
Price Target upside: 68.45%
Orla Mining Ltd. (NYSE:ORLA) is one of the best value stocks.
TheFly reported on March 19 that Orla Mining Ltd. (NYSE:ORLA) released its fourth-quarter 2025 results, reporting revenue of $378.5 million, up from $92.8 million the previous year. The company highlighted the strong integration of Musselwhite, which is contributing significantly to production and cash flow. Early exploration outcomes indicate potential near-term reserve and resource growth, while Camino Rojo demonstrated resilience despite operational challenges, and the sulphide underground project is progressing.
In Nevada, construction preparations are underway for a mid-year start on the company’s third mine. Leadership emphasized disciplined financial management, a commitment to safety and environmental standards, and a robust operational foundation to support future value creation.
On March 18, ORLA announced it received the Environmental Impact Assessment (MIA) from Mexico’s Secretariat of Environment and Natural Resources for its Camino Rojo Mine in Zacatecas. With this approval, the company now holds all required permits, including the Change of Land Use, to complete the oxide open-pit and begin construction of an underground exploration decline, expected to start in the second half of 2026. ORLA has also submitted an updated technical report reflecting the project’s recent preliminary economic assessment.
Orla Mining Ltd. (NYSE:ORLA) is a Canadian gold and copper producer advancing low‑cost, sustainable mining projects in Mexico, Panama, and North America, focused on long‑term value through efficient resource development and responsible operations.
2. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Price Target Upside: 71.60%
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the best value stocks to invest in.
TheFly reported on March 16 that Wells Fargo maintained an Overweight rating on BMRN with a $75 price target. The firm noted that BioMarin discontinued three Phase 2 Voxzogo studies in Turner Syndrome, SHOX-deficiency, and ACAN-deficiency due to cases of Slipped Capital Femoral Epiphysis observed in investigator-sponsored trials. Wells Fargo views the safety risk as specific to certain indications rather than the drug’s mechanism, and considers BMRN’s outlook less dependent on Voxzogo. The firm indicated it remains supportive and sees the shares as a buying opportunity in the event of price weakness.
On March 12, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported positive new results from ongoing clinical trials and real-world studies of Voxzogo (vosoritide) in children with achondroplasia. The findings highlight the benefits of early treatment, demonstrating sustained multi-year growth improvements, enhanced body proportionality, and increased arm span compared to untreated children.
Analyses also showed durable height gains, stable arm-to-height ratios, and significant improvements in body mass index for those who began treatment before age two. Additional real-world data from patients in Japan, Europe, and the U.S. will be presented at the 2026 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting in Baltimore, reinforcing the established efficacy and safety profile of Voxzogo.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biotechnology company that develops and commercializes therapies for rare genetic diseases, including enzyme‑replacement and gene therapies, improving treatment options for patients with serious, often life‑limiting conditions.
1. VEON Ltd. (NASDAQ:VEON)
Price Target upside: 80.86%
VEON Ltd. (NASDAQ:VEON) is one of the best value stocks.
TheFly recently reported on March 25 that VEON announced that its Ukrainian subsidiary, Uklon, expanded its mobility offerings by introducing a new “Travel” service. The service allows users to book domestic and international bus tickets directly within the Uklon app, building on its existing ride-hailing, delivery, and adtech capabilities.
By adding intercity and cross-border travel, Uklon is evolving into a full-service mobility platform, aiming to provide users with a convenient way to plan trips amid limited air travel and high rail demand. The beta launch targets growing regional demand and positions Uklon to capture a larger share of transportation spending from its established base of 3.8 million monthly active users.
In a similar context, on March 10, VEON Ltd. (NASDAQ:VEON)’s Pakistani subsidiary, Jazz, achieved a major operational milestone by securing 190 MHz of spectrum in a government-conducted auction, the largest allocation in the country. The acquisition significantly expands mobile bandwidth, strengthening Pakistan’s digital infrastructure and enabling faster broadband and next-generation services.
The spectrum includes multiple bands, 3500 MHz, 2600 MHz, 2300 MHz, and 700 MHz, allowing Jazz to enhance network capacity, broaden connectivity, and support innovative digital solutions. Serving over 100 million users, Jazz aims to leverage the additional spectrum to scale high-quality mobile broadband nationwide, invest in network upgrades, and continue advancing AI-enabled services and digital inclusion across Pakistan.
VEON Ltd. (NASDAQ:VEON) is a global telecommunications company providing mobile, data and digital services across emerging markets in Asia, Africa and Europe, focusing on connectivity, digital solutions and customer‑centric offerings to drive growth and engagement.
While we acknowledge the potential of VEON to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VEON and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
